ERBB2 and breast cancer: Immunohistochemistry (IHC) staining revealed higher resistin expression in the 154 tumor tissue specimens than in the 42 normal, healthy tissue specimens (Fig. 1A) and much stronger resistin staining in HER2+ and TNBC tumor subtypes than in luminal A and luminal B disease specimens (Fig. 1B), suggesting that resistin facilitates the progression of breast cancer.